The previous Secretary of State had regular discussions on a range of issues with those ministers. Officials are working closely together on the design of the UK Shared Prosperity Fund to ensure it supports a range of Government priorities.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4098", "label" : {"_value" : "Biography information for Dr Thérèse Coffey"} } , "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"} , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"} , "dateOfAnswer" : {"_value" : "2019-07-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-30T09:00:06.243Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Environment Protection: UK Shared Prosperity Fund"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, what discussions he has had with the (a) Chancellor of the Exchequer and (b) Secretary of State for Housing, Communities and Local Government on ensuring the UK Shared Prosperity Fund contributes to the achievement of the goals set out in the 25 Year Environment Plan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"} } , "tablingMemberConstituency" : {"_value" : "Ceredigion"} , "tablingMemberPrinted" : [{"_value" : "Ben Lake"} ], "uin" : "278577"} , {"_about" : "http://data.parliament.uk/resources/1139868", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139868/answer", "answerText" : {"_value" : "
The Ministry of Defence takes very seriously its obligation to provide the best possible medical treatment for Service personnel wounded on operational service. The quality of care delivered by the Defence Medical Services (DMS) is directly related to the thoroughness with which we prepare our deployed surgical teams for the sorts of serious injuries they will encounter.<\/p>
This training is delivered through a range of different courses and exercises, many of which employ complex simulation models such as programmable mannequins. However, simulators are currently unable to replace all trauma training. Even the most sophisticated of them are not technologically advanced enough to respond physiologically to complex surgical procedures. At present, the only means for our surgical teams to get the necessary training in the control of real-time internal haemorrhage from combat injury is through live tissue training (LTT).<\/p>
Up to twice a year, members of the DMS attend surgical training exercises in Denmark, during which live but fully anaesthetised pigs are given bullet and blast wounds which are then treated in real-time exercises by surgical teams. The animals are unconscious during the entire exercise, and feel no pain. They are attended at all times by veterinary staff, who may withdraw them at any time for any reason, and the animals are humanely put down at the end of the training procedures without recovering consciousness.<\/p>
The DMS have collaborated on a number of research programmes into simulator technology, and constantly monitors the latest developments, especially where they might in future offer an alternative means of delivering this specialised but vital training.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1487", "label" : {"_value" : "Biography information for Mr Tobias Ellwood"} } , "answeringMemberConstituency" : {"_value" : "Bournemouth East"} , "answeringMemberPrinted" : {"_value" : "Mr Tobias Ellwood"} , "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-23T13:09:59.94Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Defence Medical Services: Training"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Defence, what his Department's policy is on participation of military surgeons in overseas training exercises involving animals that have been shot or otherwise injured with offensive weapons for the purpose of that exercise.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"} } , "tablingMemberConstituency" : {"_value" : "Ceredigion"} , "tablingMemberPrinted" : [{"_value" : "Ben Lake"} ], "uin" : "278578"} , {"_about" : "http://data.parliament.uk/resources/1139869", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139869/answer", "answerText" : {"_value" : "
The Defence Science and Technology Laboratory (Dstl) at Porton Down, Wiltshire, is licensed by the Home Office to conduct the Ministry of Defence's in-house research involving the use of animals.<\/p>
In 2017 and 2018, no animals were used in scientific procedures at Dstl Porton Down under a multiple generic licence. Dstl does not hold licences of this type.<\/p>
Animals are used in experiments to develop new vaccines, therapies and treatments that save the lives of UK military and can benefit civilians. Chemical and biological weapons are a real and present threat. That is why Dstl continues its vital work in providing better protection against the use of these agents and against conventional threats.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4032", "label" : {"_value" : "Biography information for Stuart Andrew"} } , "answeringMemberConstituency" : {"_value" : "Pudsey"} , "answeringMemberPrinted" : {"_value" : "Stuart Andrew"} , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "278580"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-22T16:19:42.7Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Dstl: Animal Experiments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Defence, how many of the 3,865 animals used in scientific procedures at DSTL Porton Down in 2017 were experimented upon under a multiple generic licence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"} } , "tablingMemberConstituency" : {"_value" : "Ceredigion"} , "tablingMemberPrinted" : [{"_value" : "Ben Lake"} ], "uin" : "278579"} , {"_about" : "http://data.parliament.uk/resources/1139870", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139870/answer", "answerText" : {"_value" : "
The Defence Science and Technology Laboratory (Dstl) at Porton Down, Wiltshire, is licensed by the Home Office to conduct the Ministry of Defence's in-house research involving the use of animals.<\/p>
In 2017 and 2018, no animals were used in scientific procedures at Dstl Porton Down under a multiple generic licence. Dstl does not hold licences of this type.<\/p>
Animals are used in experiments to develop new vaccines, therapies and treatments that save the lives of UK military and can benefit civilians. Chemical and biological weapons are a real and present threat. That is why Dstl continues its vital work in providing better protection against the use of these agents and against conventional threats.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4032", "label" : {"_value" : "Biography information for Stuart Andrew"} } , "answeringMemberConstituency" : {"_value" : "Pudsey"} , "answeringMemberPrinted" : {"_value" : "Stuart Andrew"} , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "278579"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-22T16:19:42.747Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Dstl: Animal Experiments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Defence, how many of the 1,941 animals used in scientific procedures at DSTL Porton Down in 2018 were experimented upon under a multiple generic licence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"} } , "tablingMemberConstituency" : {"_value" : "Ceredigion"} , "tablingMemberPrinted" : [{"_value" : "Ben Lake"} ], "uin" : "278580"} , {"_about" : "http://data.parliament.uk/resources/1136243", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1136243/answer", "answerText" : {"_value" : "
The Government maintains that leaving the European Union with a deal is the best exit outcome and has strongly expressed its opposition to leaving without a deal, in line with the position consistently expressed by Parliament. However, leaving without a deal on 31 October 2019 remains the legal default at the end of the Article 50 extension period if no withdrawal agreement is agreed. Therefore, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a \u2018no deal\u2019 scenario.<\/p>
The Department continues to work closely with the devolved administrations, industry trade bodies and suppliers, the National Health Service and our other main stakeholders to ensure that we are prepared for leaving the EU without a deal in October.<\/p>
On 26 June, we wrote to suppliers of medicines to the United Kingdom from or via the EU or wider European Economic Area (EEA) setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential \u2018no deal\u2019 exit scenario on 31 October. Further details can be found at the following link:<\/p>
https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a><\/p> We recognise that some medical radioisotopes have a short shelf life and cannot be stockpiled. Therefore, as part of the Department\u2019s contingency planning ahead of a possible March/April 2019 \u2018no deal\u2019 scenario, where medical radioisotope products were imported to the UK from the EU or EEA via road haulage and roll-on, roll-off sea, road and rail routes, we asked suppliers to ensure that they had plans in place to air freight those products to avoid any border delays that may have arisen in a no-deal scenario. We worked extensively with these suppliers to ensure plans were in place and are continuing to do so, to ensure that robust contingency arrangements continue to be in place ahead of a possible \u2018no deal\u2019 EU exit on 31 October.<\/p> <\/p> The Department has not had discussions with the Civil Aviation Agency in relation to this issue as they are the Government\u2019s expert arm\u2019s length body for the safety, security and economic regulation of civil aviation in the UK. We are, however, working very closely with the Department for Transport.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
}
, "answeringMemberConstituency" : {"_value" : "Wimbledon"}
, "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
, "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "272240"}
, {"_value" : "272241"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-10T16:43:03.51Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with representatives of suppliers of medical radioisotopes on the feasibility of using air freight to import their products in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"}
}
, "tablingMemberConstituency" : {"_value" : "Ceredigion"}
, "tablingMemberPrinted" : [{"_value" : "Ben Lake"}
], "uin" : "272239"}
, {"_about" : "http://data.parliament.uk/resources/1136244", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1136244/answer", "answerText" : {"_value" : " The Government maintains that leaving the European Union with a deal is the best exit outcome and has strongly expressed its opposition to leaving without a deal, in line with the position consistently expressed by Parliament. However, leaving without a deal on 31 October 2019 remains the legal default at the end of the Article 50 extension period if no withdrawal agreement is agreed. Therefore, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a \u2018no deal\u2019 scenario.<\/p> The Department continues to work closely with the devolved administrations, industry trade bodies and suppliers, the National Health Service and our other main stakeholders to ensure that we are prepared for leaving the EU without a deal in October.<\/p> On 26 June, we wrote to suppliers of medicines to the United Kingdom from or via the EU or wider European Economic Area (EEA) setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential \u2018no deal\u2019 exit scenario on 31 October. Further details can be found at the following link:<\/p> https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a><\/p> We recognise that some medical radioisotopes have a short shelf life and cannot be stockpiled. Therefore, as part of the Department\u2019s contingency planning ahead of a possible March/April 2019 \u2018no deal\u2019 scenario, where medical radioisotope products were imported to the UK from the EU or EEA via road haulage and roll-on, roll-off sea, road and rail routes, we asked suppliers to ensure that they had plans in place to air freight those products to avoid any border delays that may have arisen in a no-deal scenario. We worked extensively with these suppliers to ensure plans were in place and are continuing to do so, to ensure that robust contingency arrangements continue to be in place ahead of a possible \u2018no deal\u2019 EU exit on 31 October.<\/p> <\/p> The Department has not had discussions with the Civil Aviation Agency in relation to this issue as they are the Government\u2019s expert arm\u2019s length body for the safety, security and economic regulation of civil aviation in the UK. We are, however, working very closely with the Department for Transport.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
}
, "answeringMemberConstituency" : {"_value" : "Wimbledon"}
, "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
, "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "272239"}
, {"_value" : "272241"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-10T16:43:03.557Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what representations he has received from the suppliers of medical radioisotopes on the potential risk to the import of those instruments in the event that the UK leaves the EU without an agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"}
}
, "tablingMemberConstituency" : {"_value" : "Ceredigion"}
, "tablingMemberPrinted" : [{"_value" : "Ben Lake"}
], "uin" : "272240"}
, {"_about" : "http://data.parliament.uk/resources/1136245", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1136245/answer", "answerText" : {"_value" : " The Government maintains that leaving the European Union with a deal is the best exit outcome and has strongly expressed its opposition to leaving without a deal, in line with the position consistently expressed by Parliament. However, leaving without a deal on 31 October 2019 remains the legal default at the end of the Article 50 extension period if no withdrawal agreement is agreed. Therefore, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a \u2018no deal\u2019 scenario.<\/p> The Department continues to work closely with the devolved administrations, industry trade bodies and suppliers, the National Health Service and our other main stakeholders to ensure that we are prepared for leaving the EU without a deal in October.<\/p> On 26 June, we wrote to suppliers of medicines to the United Kingdom from or via the EU or wider European Economic Area (EEA) setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential \u2018no deal\u2019 exit scenario on 31 October. Further details can be found at the following link:<\/p> https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a><\/p> We recognise that some medical radioisotopes have a short shelf life and cannot be stockpiled. Therefore, as part of the Department\u2019s contingency planning ahead of a possible March/April 2019 \u2018no deal\u2019 scenario, where medical radioisotope products were imported to the UK from the EU or EEA via road haulage and roll-on, roll-off sea, road and rail routes, we asked suppliers to ensure that they had plans in place to air freight those products to avoid any border delays that may have arisen in a no-deal scenario. We worked extensively with these suppliers to ensure plans were in place and are continuing to do so, to ensure that robust contingency arrangements continue to be in place ahead of a possible \u2018no deal\u2019 EU exit on 31 October.<\/p> <\/p> The Department has not had discussions with the Civil Aviation Agency in relation to this issue as they are the Government\u2019s expert arm\u2019s length body for the safety, security and economic regulation of civil aviation in the UK. We are, however, working very closely with the Department for Transport.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
}
, "answeringMemberConstituency" : {"_value" : "Wimbledon"}
, "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
, "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "272239"}
, {"_value" : "272240"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-10T16:43:03.603Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with the Civil Aviation Authority on the potential risk to the import of medical radioisotopes in the event that the UK leaves the EU without an agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"}
}
, "tablingMemberConstituency" : {"_value" : "Ceredigion"}
, "tablingMemberPrinted" : [{"_value" : "Ben Lake"}
], "uin" : "272241"}
, {"_about" : "http://data.parliament.uk/resources/1136246", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1136246/answer", "answerText" : {"_value" : " The Government maintains that leaving the European Union with a deal is the best exit outcome and has strongly expressed its opposition to leaving without a deal, in line with the position consistently expressed by Parliament. However, leaving without a deal on 31 October 2019 remains the legal default at the end of the Article 50 extension period if no withdrawal agreement is agreed. Therefore, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a \u2018no deal\u2019 scenario.<\/p> <\/p> The Department continues to work closely with the devolved administrations, relevant EU member states, industry trade bodies and suppliers, the National Health Service and our other main stakeholders to ensure that we are prepared for leaving the EU without a deal in October.<\/p> On 26 June, we wrote to suppliers of medicines to the United Kingdom from or via the EU or European Economic Area setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential \u2018no deal\u2019 scenario on 31 October. Further details can be found at the following link:<\/p> https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a><\/p> We recognise that suppliers may incur additional storage costs for stockpiling medicines or switching to air freight We have been working closely with industry to minimise costs and support medicine suppliers taking part in the contingency programme.<\/p> The provision for additional warehouse space procured for a possible 29 March \u2018no deal\u2019 exit remains available for the 31 October deadline. The Department expects to spend around £11 million over the life of these contracts.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
}
, "answeringMemberConstituency" : {"_value" : "Wimbledon"}
, "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
, "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "272243"}
, {"_value" : "272244"}
, {"_value" : "272245"}
, {"_value" : "272246"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-10T16:43:54.97Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with his EU counterparts on the supply of medicines from other EU member states in the event that the UK leaves the EU without an agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4630", "label" : {"_value" : "Biography information for Ben Lake"}
}
, "tablingMemberConstituency" : {"_value" : "Ceredigion"}
, "tablingMemberPrinted" : [{"_value" : "Ben Lake"}
], "uin" : "272242"}
, {"_about" : "http://data.parliament.uk/resources/1136247", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1136247/answer", "answerText" : {"_value" : " The Government maintains that leaving the European Union with a deal is the best exit outcome and has strongly expressed its opposition to leaving without a deal, in line with the position consistently expressed by Parliament. However, leaving without a deal on 31 October 2019 remains the legal default at the end of the Article 50 extension period if no withdrawal agreement is agreed. Therefore, as a responsible Government, we will continue to prepare to minimise any disruption to the supply of medicines and medical products in a \u2018no deal\u2019 scenario.<\/p> <\/p> The Department continues to work closely with the devolved administrations, relevant EU member states, industry trade bodies and suppliers, the National Health Service and our other main stakeholders to ensure that we are prepared for leaving the EU without a deal in October.<\/p> On 26 June, we wrote to suppliers of medicines to the United Kingdom from or via the EU or European Economic Area setting out our continuing multi-layered approach to ensure the continuity of supply of all medicines and medical products in a potential \u2018no deal\u2019 scenario on 31 October. Further details can be found at the following link:<\/p>